The Poly-Agonist Frontier: Retatrutide, CagriSema, and the Evolution of Metabolic Therapy 🔥🧠
Explore the Poly-Agonist Frontier: How Retatrutide, Mazdutide, and CagriSema combine Glucagon activation and Amylin synergy to rewrite metabolic therapy.
🎧 Listen to this article:
🔬 BEYOND THE DUAL-AGONIST CEILING
Metabolic therapy is advancing rapidly. We began by decoding the gut-brain axis through GLP-1 mono-agonists like Semaglutide, which suppress hunger in the hypothalamus. We then advanced to dual-agonists like Tirzepatide, stacking GLP-1 with GIP to enhance insulin regulation and amplify appetite suppression.
However, simple caloric restriction has a physiological ceiling. The next phase of metabolic medicine is not just about stopping intake—it is about directly increasing energy expenditure and triggering alternative fullness signals in the brain. This brings us to poly-agonists: compounds that add glucagon activation and amylin synergy into the mix.